Pharmaceutical strategies for preventing toxicity and promoting antioxidant and anti-inflammatory actions of bilirubin

• Egile Nagusiak: Alessio Nocentini (Egilea), Alessandro Bonardi (Egilea), Simone Pratesi (Egilea), Paola Gratteri (Egilea), Carlo Dani (Egilea), Claudiu T. Supuran (Egilea)
• Formatua: Liburua
• Argitaratua: Taylor & Francis Group, 2022-12-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Bilirubin (BR) is the final product of haem catabolism. Disruptions along BR metabolic/transport pathways resulting from inherited disorders can increase plasma BR concentration (hyperbilirubinaemia). Unconjugated hyperbilirubinemia may induce BR accumulation in brain, potentially causing irreversib...